Search research articles
Contact Us
Filters
Showing results (41-50 of 105) with videos related to
Page
of 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Gynecologic Oncology
|
September 3, 2021
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer
Katherine C Fuh, Michael A Bookman, Joyce F Liu, et al.
Nature Communications
|
August 30, 2017
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Ioannis K Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, et al.
Gynecologic Oncology Reports
|
February 22, 2020
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Elizabeth K Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2020
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2021
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Joyce F Liu, Niya Xiong, Susana M Campos, et al.
Gynecologic Oncology Reports
|
March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Oncotarget
|
February 13, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, et al.
Molecular Cancer Therapeutics
|
January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 105) with videos related to
Sort By:
Page
of 11
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
Joyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Gynecologic Oncology
|
September 3, 2021
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer
Katherine C Fuh, Michael A Bookman, Joyce F Liu, et al.
Nature Communications
|
August 30, 2017
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
Ioannis K Zervantonakis, Claudia Iavarone, Hsing-Yu Chen, et al.
Gynecologic Oncology Reports
|
February 22, 2020
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Elizabeth K Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2020
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 11, 2021
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Joyce F Liu, Niya Xiong, Susana M Campos, et al.
Gynecologic Oncology Reports
|
March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Oncotarget
|
February 13, 2016
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, et al.
Molecular Cancer Therapeutics
|
January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Page
of 11